Why This AI Stock Was Rated a “Strong Buy” on Yahoo Finance

Since heart disease is the world's #1 leading cause of death, it's no surprise when an AI company working to solve it ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ Unsubscribe A Message from HeartSciences Since heart disease is the world’s #1 leading cause of death, it’s no surprise when an AI company working to solve it gets a “Strong Buy” rating from analysts—and a 270% 1-year growth target. For decades, millions with heart disease have gone undiagnosed because effective heart diagnostics are expensive and require cardiologists. But this company is bridging the gap. Their AI-ECG, developed with Mount Sinai, brings specialist-grade insights to routine frontline exams so issues will be caught faster and more affordably by frontline doctors.  And they’re hitting several major milestones as we speak: First commercial customer for their software platform, a cardiology center providing services to the UK’s NHS, one of the largest healthcare networks in the world FDA Breakthrough Device Designation, providing priority review and a faster path to market New foundational U.S. patent issued, bringing the total to 44 granted patents and further protecting their AI-ECG technology from competitors FDA submission for their device expected for summer 2025 While they’re already public, investors have an opportunity not available on the public exchange: $3.50 units that include 1 share of convertible preferred stock + 1 warrant.  Learn more and invest today. Thank you for subscribing to DividendStocks.com's daily newsletter for dividend and income investors that covers ex-dividend stocks, new dividend declarations, dividend stock ideas, and the latest market news.   This message is a paid advertisement sent on behalf of HeartSciences, a third-party advertiser of DividendStocks.com and MarketBeat.     This is a paid advertisement for HeartSciences Regulation A+ offering. Please read the offering circular at https://invest.heartsciences.com/     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.   © 2006-2025 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: 5 Stocks Poised to Soar Under Trump's Presidency (Click to Opt-In)

Share on Facebook

Share on Twitter

Share on Google+

Share on LinkedIn

Subscribe to receive free email updates: